Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAd3-Marburg vaccine in healthy adults
NCT05817422Phase 2Completed
- Sponsor
- Sabin Vaccine Institute
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of ChAd3-MARV in Marburg virus disease (MVD), sponsored by Sabin Vaccine Institute. Started Oct 2023; status: completed.
02
Drugs
ChAd3-MARV
03
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT05817422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817422.